Back to top
more

Cassava Sciences (SAVA)

(Real Time Quote from BATS)

$25.82 USD

25.82
746,533

-0.39 (-1.49%)

Updated Nov 4, 2024 03:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cassava Sciences (SAVA) Jumps: Stock Rises 9.2%

by Zacks Equity Research

Cassava Sciences (SAVA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Cassava Sciences (SAVA) in Focus: Stock Moves 8.5% Higher

by Zacks Equity Research

Cassava Sciences (SAVA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

    Rimmi Singhi headshot

    Add Value to Your Portfolio With 5 High Earnings Yield Picks

    by Rimmi Singhi

    If other factors are constant while comparing stocks, the one with a higher earnings yield has the potential to provide comparatively greater returns.

    Company News for Apr 24, 2020

    by Zacks Equity Research

    Companies In The News Are: LLY, SAVA, FLR, LYTS

    What Lies Ahead for Cassava Sciences (SAVA) in Q4 Earnings?

    by Zacks Equity Research

    During the Q4 investors' call, Cassava Sciences (SAVA) is likely to provide an update on its lead candidate PT-125, which is being developed for the treatment of Alzheimer's disease.

    The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences

    Tirthankar Chakraborty headshot

    Buy Multibagger Stocks as Odds of a Rally Are High in 2020

    by Tirthankar Chakraborty

    Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.

    Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics

    by Zacks Equity Research

    Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics

    Nalak Das headshot

    5 Stocks With Recent Price Strength for Spectacular Returns

    by Nalak Das

    Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

    Company News For Jan 3, 2020

    by Zacks Equity Research

    Companies in the news are: CMG, SAVA, RCON, IPHA

    The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma

    5 Stocks to Soar in 2020 After Solid Gains in 2019

    by Zacks Equity Research

    U.S. stocks rallied to attained fresh all-time highs in 2019, as the momentum continued in 2020. Here are five stocks that are poised to grow.

    Sanghamitra Saha headshot

    Biotech Rally Sends Nasdaq to 9000: ETFs in Focus

    by Sanghamitra Saha

    Some biotech stocks have contributed materially to the Nasdaq's 1000-point gain since Aug 27, 2018 and helped it notch a record 9,000 on Dec 26.

    Top Ranked Momentum Stocks to Buy for December 10th

    by Zacks Equity Research

    Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 10th

    Top Ranked Momentum Stocks to Buy for December 4th

    by Zacks Equity Research

    Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 4th

    Kinjel Shah headshot

    6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day

    by Kinjel Shah

    Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.